| 36.9562 -0.454 (-1.21%) | 06-02 10:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.05 | 1-year : | 52.15 |
| Resists | First : | 40.28 | Second : | 44.65 |
| Pivot price | 39.48  |
|||
| Supports | First : | 33.22 | Second : | 27.64 |
| MAs | MA(5) : | 38.06 |
MA(20) : | 39.96  |
| MA(100) : | 32.99 |
MA(250) : | 33.15 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 9 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 44.65 | Low : | 25.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TGTX ] has closed above bottom band by 8.5%. Bollinger Bands are 10.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.25 - 38.51 | 38.51 - 38.72 |
| Low: | 36.11 - 36.47 | 36.47 - 36.74 |
| Close: | 36.91 - 37.4 | 37.4 - 37.77 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Tue, 02 Jun 2026
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference - The Globe and Mail
Tue, 02 Jun 2026
CEO Michael Weiss joins Goldman Sachs healthcare fireside chat June 9 - Stock Titan
Mon, 01 Jun 2026
In MS trial, BRIUMVI left 83% of untreated patients with no disease activity - Stock Titan
Mon, 01 Jun 2026
TG Therapeutics, Inc. (TGTX) Stock Analysis: Potential 26.52% Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 153 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 70.2 (%) |
| Shares Short | 28,110 (K) |
| Shares Short P.Month | 28,730 (K) |
| EPS | 2.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.51 |
| Profit Margin | 65.9 % |
| Operating Margin | 16.9 % |
| Return on Assets (ttm) | 8.5 % |
| Return on Equity (ttm) | 112.5 % |
| Qtrly Rev. Growth | 69.5 % |
| Gross Profit (p.s.) | 3.79 |
| Sales Per Share | 4.57 |
| EBITDA (p.s.) | 0.97 |
| Qtrly Earnings Growth | 300 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | 12.91 |
| PEG Ratio | 1.6 |
| Price to Book value | 8.17 |
| Price to Sales | 8.07 |
| Price to Cash Flow | -405.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|